Deena Rose Altman

Deena Rose Altman

Auto-generated profile, based on publicly available information

Deena Rose Altman

Icahn School of Medicine at Mount Sinai

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
AWAnia Wajnberg
Ania Wajnberg
FAFatima Amanat
Fatima Amanat
AFAdolfo Firpo
Adolfo Firpo
DADeena R. Altman
Deena R. Altman
MBMark J. Bailey
Mark J. Bailey
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
SARS-CoV-2 antibodies persist: As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science , this issue p. 1227

17 July 2020 in Science
Verified
Journal Article
Open access
PDF file
AGAna Silvia Gonzalez-Reiche
Ana Silvia Gonzalez-Reiche
MHMatthew M. Hernandez
Matthew M. Hernandez
MSMitchell J. Sullivan
Mitchell J. Sullivan
BCBrianne Ciferri
Brianne Ciferri
HAHala Alshammary
Hala Alshammary
HBHarm van Bakel
Harm van Bakel
Blighted Gotham: Deaths caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City (NYC) during the spring of 2020 have vastly exceeded those reported in China and many other countries. What were the early events that led to such a severe outbreak? Gonzalez-Reiche et al. sampled some of the early patients seeking assistance in February and March of 2020 at the Mount Sinai Health System. Phylogenetic analysis of virus sequences in these people, who were drawn from across NYC, showed that the virus had been independently introduced many times from Europe and elsewhere in the United States. Subsequent clusters of community transmission occurred. The focus of infection in NYC is a marker of the role this city plays as a two-way hub for human movement. Science this issue p. 297

15 September 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SLSean T.H. Liu
Sean T.H. Liu
HLHung-Mo Lin
Hung-Mo Lin
IBIan Baine
Ian Baine
AWAnia Wajnberg
Ania Wajnberg
JGJeffrey P. Gumprecht
Jeffrey P. Gumprecht
NBNicole M. Bouvier
Nicole M. Bouvier

25 November 2019 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
POPedro Oliveira
Pedro Oliveira
JRJohn W. Ribis
John W. Ribis
EGElizabeth M. Garrett
Elizabeth M. Garrett
DTDominika Trzilova
Dominika Trzilova
AKAlex Kim
Alex Kim
GFGang Fang
Gang Fang

17 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AWAnia Wajnberg
Ania Wajnberg
FAFatima Amanat
Fatima Amanat
AFAdolfo Firpo-Betancourt
Adolfo Firpo-Betancourt
DADeena R. Altman
Deena R. Altman
MBMark J. Bailey
Mark J. Bailey
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality and longevity of the antibody response to the virus remain unanswered. Here we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein, based on a dataset of 19,860 individuals screened at Mount Sinai Health System in New York City. We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody responses and that these titers are stable for at least the near-term future. One Sentence Summary: Antibody responses induced by natural mild-to-moderate SARS-CoV-2 infection are robust, neutralizing and are stable for at least 3 months.

1 November 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JCJaclyn A Cusumano
Jaclyn A Cusumano
ADAmy C Dupper
Amy C Dupper
YMYesha Malik
Yesha Malik
EGElizabeth M Gavioli
Elizabeth M Gavioli
JBJaspreet Banga
Jaspreet Banga
DADeena Rose Altman
Deena Rose Altman
Previous viral pandemics have shown that secondary bacterial infections result in higher morbidity and mortality, with Staphylococcus aureus as the primary causative pathogen. The impact of secondary S. aureus bacteremia on mortality in patients infected with SARS-CoV-2 remains unknown. This was a retrospective, observational case series of patients with COVID-19 disease who developed secondary S. aureus bacteremia across two New York City hospitals. The primary endpoint was to describe 14-day and 30-day hospital mortality rates of patients infected with COVID-19 and S. aureus bacteremia. Secondary endpoints included predictors of 14-day and 30-day hospital mortality in patients infected with COVID-19 and S. aureus bacteremia. A total of 42 hospitalized patients for COVID-19 with secondary S. aureus bacteremia were identified. Of these patients, 23 (54.8 %) and 28 (66.7%) died at 14 days and 30 days, respectively, from their first positive blood culture. Multivariate analysis identified hospital-onset bacteremia (≥4 days from date of admission) and age as significant predictors of 14-day hospital mortality, and Pitt bacteremia score as a significant predictor of 30-day hospital mortality (odds ratio [OR] 11.9 [95% confidence interval [CI] 2.03-114.7], p=0.01; (OR 1.10 [95% CI 1.03-1.20], p=0.02); and (OR 1.56 [95% CI 1.19-2.18], p=0.003), respectively. Bacteremia with S. aureus is associated with high mortality rates in patients hospitalized with COVID-19 infection. Further investigation is warranted to understand the impact of COVID-19 and secondary S. aureus bacteremia.